anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: Drowning is a leading cause of unintentional death. Ongoing efforts are dedicated to preventing these tragic incidents. Our aim was to evaluate whether demographic, environmental and epidemiological characteristics of drowned children influence their prognosis.
METHODS: Single-centre retrospective study spanning 12 years. Each patient's record included: age, sex, place of residence, presence of siblings, season of incident, location of event, associated trauma, loss of consciousness, need for cardiopulmonary resuscitation, intubation, admission to intensive care unit, length of stay and mortality.
RESULTS: We enrolled 60 patients, with a mean age of 5.9 ± 3.4 years; 63.5% were male. Children who did not reside near the sea were significantly older than those who did (p = 0.01) and faced a higher risk of experiencing sea-related drowning (p = 0.05). No patients died. Loss of consciousness and need for cardiopulmonary resuscitation were recorded in 30 and 19 patients respectively. Seven patients sustained trauma. Only one patient requiring intubation. Pool-related drowning were associated with a higher incidence of needing cardiopulmonary resuscitation (p = 0.02). The need for cardiopulmonary resuscitation (p = 0.05) and the occurrence of trauma (p = 0.02) were identified as risk factors for a longer hospitalisation.
CONCLUSION: Prevention and early initiation of cardiopulmonary resuscitation are essential for achieving a favourable prognosis. Identifying demographic and environmental risk factors may help identify other effective preventive measures.
The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
Each subject will be asked to sign the Informed Consent Form (ICF). A total of 46 subjects will be enrolled, 23 for each group will be randomized with a 1:1 ratio and allocated to one treatment group (blinded assignment). Group 1: Treatment with OR-AT0222 and Group 2: Treatment with Placebo. The patients will be asked to apply 1-2 drops of the gel on their ulcers three times a day for 7 days and to record the aphthous pain level based on visual analogue scale (VAS) using a number scale from 0 to 10, with 0 no pain at all and 10 the most severe pain. The patients have to refrain from eating and drinking for at least 30 minutes after gel application. The study will also assess tolerability and safety (adverse events). At day 8, the patients will be examined again. Complete healing (the time when the pseudomembrane and the erythematous border disappear) will be confirmed by clinician examination at the end of the treatment period. Reduction of the number of ulcers respect to baseline and percent of lesions with complete healing will be also assessed
Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
Brain-dead human subjects (decedents) were recently introduced as a potential preclinical experimental model in xenotransplantation. Brain death is associated with major pathophysiological changes, eg, structural injury and cell infiltration in vital organs, and major hormonal, metabolic, inflammatory, and hemodynamic changes. In 2 of the 3 initial experiments, the design of the experiments resulted in little or no new information becoming available. In the third, the experiment was unfortunately unsuccessful as neither of the 2 pig kidneys transplanted into the decedent functioned adequately. Failure may well have been associated with the effects of brain death, but an immune/inflammatory response to the xenograft could not be excluded. Subsequently, 2 further pig kidney transplants and 2 pig heart transplants have been carried out in human decedents, but again the data obtained do not add much to what is already known. In view of the profound changes that take place during and after brain death, it may prove difficult to determine whether graft failure or dysfunction results from the effects of brain death or from an immune/inflammatory response to the xenograft. A major concern is that, if the results are confusing, they may impact decisions relating to the introduction of clinical xenotransplantation.
The intent of this protocol is to measure blood flow in the gastrocnemius muscle in patients with documented peripheral artery disease before and after exposure to 670 nm light energy. The study consists of one visit. Blood flow measurement will be performed using contrast enhanced ultrasound, a method by which ultrasound contrast is continuously infused into the blood stream. Ultrasound records images in the area of interest and flow is related to the intensity of the contrast in each image. Blood will be drawn to measure nitric oxide metabolites. The study is designed to consist of one visit. However, if the protocol changes or the data quality initially collected is uninterpretable, subjects may be asked to return to allow for a standard methodology across all participants. In this case, the subjects who are asked to return will be subject to the same informed consent process a second time. The two visits will be at least one week apart to further reduce the already minimal risks of the study. This will also limit the number of study participants required to gather the necessary data to complete the study, thereby limiting the risks of the study to a smaller number of participants.
Chronic pain is a condition that affects the most fundamental aspects of quality of life. Treatment for chronic pain is challenging and usually takes the form of opioid medication therapy. But chronic opioid therapy is also associated with high rates of emergency department use, drug diversion, addiction, and unintentional overdose deaths. The new RI Medicaid Chronic Pain Initiative (CPI) targets patients who are both high emergency department users and experiencing chronic pain. In the CPI, patients can be prescribed an integrated treatment plan of massage, chiropractic, or acupuncture therapies. This is a novel approach to chronic pain care, but retention and patient engagement are low. It is important to understand why involvement in the CPI is low, how to improve the patient experience, and how to support the prescribed CAM therapies.

This study has two aims: The first is to identify what helps to keep patients involved with the CPI program and to identify features of an ideal text-message-based program for people enrolled in the CPI. The second aim is to develop the text-message-based program (OPENtext), then find out how useful this intervention is compared to a patient navigator intervention (OPENnav) for increasing patient engagement, improving patient's motivation to manage their chronic pain, and improving patient confidence in self-managing their chronic pain condition.

Investigators will conduct qualitative interviews with patients, providers, and administrators. Goals of the interviews will be: to understand the patient experience in the CPI, including experiences with the navigation approach currently in place; to identify barriers and facilitators to CPI participation; and to learn how technology-especially cell phone text-messaging-could help support pain care and CPI engagement. These interviews will help develop a text-message-based intervention and provide feedback to existing patient navigator programming. Next, investigators will develop and test the text-message patient support intervention that will contain patient-identified topics and concerns that emerge from the qualitative interviews and topic areas discussed by a stakeholder Advisory Board. Theories of behavior change will be used to help with message development, and patients will take part in helping to test and fine-tune the intervention. Last, investigators will compare the text-message and patient navigation interventions in a randomized controlled study with 200 patients over a six-month period. Investigators will see which approach helps patients increase their involvement in the CPI and better manage their chronic pain. If successful, chronic pain patients across Medicaid programs could benefit from use of the patient navigation or the text-message intervention.
Myocarditis is clinically characterized by chest pain, arrhythmias, and heart failure, and treatment is often supportive. Mutations in DSP, a gene encoding the desmosomal protein desmoplakin, have been increasingly implicated in myocarditis. To model DSP-associated myocarditis and assess the role of innate immunity, we generated engineered heart tissues (EHTs) using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from patients with heterozygous DSP truncating variants (DSPtvs) and a gene-edited homozygous deletion cell line (DSP-/-). At baseline, DSP-/- EHTs displayed a transcriptomic signature of innate immune activation, which was mirrored by cytokine release. Importantly, DSP-/- EHTs were hypersensitive to Toll-like receptor (TLR) stimulation, demonstrating more contractile dysfunction compared with isogenic controls. Relative to DSP-/- EHTs, heterozygous DSPtv EHTs had less functional impairment. DSPtv EHTs displayed heightened sensitivity to TLR stimulation, and when subjected to strain, DSPtv EHTs developed functional deficits, indicating reduced contractile reserve compared with healthy controls. Colchicine or NF-κB inhibitors improved strain-induced force deficits in DSPtv EHTs. Genomic correction of DSP p.R1951X using adenine base editing reduced inflammatory biomarker release from EHTs. Thus, EHTs replicate electrical and contractile phenotypes seen in human myocarditis, implicating cytokine release as a key part of the myogenic susceptibility to inflammation. The heightened innate immune activation and sensitivity are targets for clinical intervention.
Each SSC session will last 2-hr during the day including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise. The 2-hr SSC will be followed by a 1-hr quiet period where infants will rest in their incubator/crib with a pad immersed with their mother breast milk for olfactory stimulation and where the control of light and noise levels will be continued. The NeuroN-QI will be done 4 times/wk for each dyad.
The solution deals with vaccine, which contains dissolvable antigens of the tapeworm insolubilized on liposomal particles with the adjuvant effect. It preparation is based on the mixture of 50 to 100 mg of lecithin and from 5 to 100 mg of lecithin and from 5 to 20 mg of cholesterol per each 10 ml of the vaccine. The mixture is solved in 10 to 15 ml of chloroform and it evaporates into the thick layer. From 0.8 to 1.5 mg of protein antigen in buffered physiological solution per each 1 ml of the vaccine is added to evaporation residue of phospholipids, whereupon, after mixing, stabilization and sonication, the vaccine is prepared for use or conservation for the possible storage. The vaccine does not have side effects in vivo and its application is simple and safe. The prophylactic agent can be used with small farm animals, e.g. rabbits.
Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
The object of the present invention is to provide  a! a cosmetic raw material which allows the uniform dispersion of a powdered silicone rubber in a cosmetic,  b! a cosmetic  i! which consists of the abovementioned cosmetic raw material and other cosmetic raw materials,  ii! which contains a uniformly dispersed powdered silicone rubber, and  iii! which has a good feeling on the fingers and skin, good spreading characteristics and a good feeling during use, and  c! a method for manufacturing such a cosmetic with good efficiency. 
     The present invention provides  a! a cosmetic raw material which is characterized by the fact that said material consists of an aqueous suspension of a powdered silicone rubber with a mean particle size of 0.1 to 500 microns,  b! a cosmetic which is characterized by the fact that said cosmetic consists of the abovementioned cosmetic material and other cosmetic materials, and  c! a cosmetic manufacturing method which is characterized by the fact that the abovementioned cosmetic raw material is mixed with other cosmetic raw materials.
Between November 2009 and December 2016, at Edouard Herriot Hospital (Lyon, France), 146 consecutive patients were treated with focal HIFU for primary localized prostate cancer. Focal therapy was offered for low or intermediate risk disease (inclusion criteria: one tumor localized by systematic and targeted biopsies based on MRI findings, Gleason ≤7). Treatment failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death.
PURPOSE:To obtain the subject promoter, containing prostaglandin D2 or J2 as an active ingredient and useful for preventing and treating dementia or various neuropathies, e.g. spinal cord or peripheral nerve injuries, diabetic neuropathy or amyotrophic lateral sclerosis. CONSTITUTION:This promoter for the production of nerve growth factors contains prostaglandin D2 or J2 as an active ingredient. The daily dose thereof is 1mug to 500mg and preferably administered in 1 to several portions. The prostaglandin D2 or J2 is mixed with a medicinal carrier or a pharmaceutical adjuvant, prepared as a parenteral injection, a drip or a crude drug, etc., and parenterally administered. The amount of the blended prostaglandin D2 or J2 in this promoter is preferably 0.2-5wt.%.
MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
A topical composition comprising a phenyl pyrazole insecticide and a solvent comprising at least one cyclic carbonate is disclosed. The solvent may comprise at least 90% by volume cyclic carbonate, and the cyclic carbonate can be ethylene carbonate, propylene carbonate, butylenes carbonate and/or glycerine carbonate. The insecticide is preferably fipronil. The composition may further include other active ingredients, and the composition is preferably in the form of a spot-on or spray-on formulation for an animal. Medical uses of the compositions in treating animals or humans are also claimed (e.g. to eradicate ectoparasites from the skin), along with kits comprising the composition.
BACKGROUND: Limb length preservation is correlated with overall survival. Successful free flap coverage of forefoot, midfoot, and hindfoot amputations can prevent more proximal below-knee amputations but is challenging in patients with multiple comorbidities. The thin superficial circumflex iliac artery perforator (SCIP) flap is well-suited for these patients, as it provides thin, pliable tissue from a favorable donor site.
METHODS: A retrospective review of all patients with distal amputations requiring coverage with a thin SCIP flap between 2016 to 2022 was performed. Patient demographics, amputation levels, and wound characteristics in addition to flap and microsurgery details were analyzed. The primary outcome was limb salvage. Secondary outcomes included partial flap necrosis, flap revision rate, and additional postoperative complications.
RESULTS: Thirty-two patients (mean age, 57.3 years) underwent reconstruction of forefoot, midfoot, and hindfoot amputations with thin SCIP flaps (mean follow-up, 36 months). Twenty-eight patients (87.5%) had diabetes, 27 (84.4%) had peripheral artery disease, and 15 (46.9%) were dialysis-dependent. Average flap size was 59.5 cm 2 and average flap thickness was 5.7 mm. Successful limb salvage was achieved in 27 patients (84.3%). Three cases (9.4%) had total flap loss. Twenty-one flaps (65.6%) had partial necrosis, of which 12 (57.1%) healed with conservative management and 7 (33.3 %) healed after late revision.
CONCLUSIONS: The thin SCIP flap is a useful option for coverage of distal pedal amputations in patients with significant comorbidities. Despite higher rates of partial flap necrosis, free flap reconstruction allowed for high rates of limb salvage in a challenging patient population.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
To provide an aerosol hairspray product substantially free of ethanol, showing an acceptable or superior product performance, and less likely to cause clogging.SOLUTION: A reservoir includes from about 40% to about 70% of a hairstyling formulation and from about 30% to about 60% of a dimethyl ether propellant. The hairstyling formulation includes water, one or two or more hairstyling polymers, and from about 0.05% to about 2% of alcohol. A spraying device is attached to a container. The spraying device includes a valve 130, the valve includes a valve housing 140, the valve housing includes a vapor tap 160, and the vapor tap includes a vapor tap area. A dip tube 170 is connected to the valve. The dip tube includes a dip tube orifice including a dip tube orifice area. A ratio of the vapor tap area to the dip tube orifice area is from about 0.005 to about 0.15.SELECTED DRAWING: Figure 1
A computing device and computer-implemented method to provide access to a private data object is described. The system uses Non-Fungible Tokens (NFT) and smart contracts as a mechanism to provide access to data. The information to which the token refers, e.g., the artwork, is viewable by everyone as part of a digital ledger network. The token is used only to determine who owns that item. The present approach offers an alternative for using NFT, so that access to the information itself to which the token is linked is controlled and negotiated by the token owner. The present invention can be applied to any IoT network that performs data collection that is of interest to companies or organizations outside the network in which the collection was performed, allowing to identify the ownership of IoT devices. Thus, enabling access control to the device's data, by their owners, directly through the blockchain.
Using a two-arm cluster randomized design, our proposed study will evaluate the comparative effectiveness of ACT, a coordinated protocol for transitioning adolescents living with HIV (ALHIV) from pediatric to adult care (Intervention Group; IG) versus the usual abrupt transfer to adult care (Control group; CG) on rates of retention in care and viral suppression, and differences in perceived psychosocial wellbeing. Twelve health facilities, two in each of the six geopolitical zones of Nigeria will be pair-matched and randomly assigned to either IG (N=6 health facilities) or CG (N=6 health facilities). A total of 216 ALHIV will be enrolled in the study over a 36-month period. The primary outcome will be the difference in the rate of retention between the groups. Secondary outcomes will be difference in the rate of viral suppression and the difference in perceived psychosocial wellbeing. Additionally, the investigators will conduct mediation/moderation analysis to examine the role of intermediate variables such as transition readiness, perceived mental health, social support, health locus of control, self-esteem and sexual risk behavior self-efficacy on the primary outcomes. Implementation factors will be assessed using the hybrid 2 model.
In December 2019, an outbreak of the 2019 novel coronavirus disease (COVID-19) caused by the SARS coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China. It has spread rapidly to other areas in China and worldwide. The most common manifestations of COVID-19 included fever, dry cough, dyspnea, myalgia, fatigue and radiographic evidence of pneumonia. Complications (acute respiratory distress syndrome, shock, acute cardiac injury, secondary infection, and acute kidney injury) and death may occur in severe cases. Recent reports showed that extrapulmonary symptoms (intestinal symptoms in 10-20% of patients) and renal failure in some patients may be associated with the interaction of the virus with angiotensin-converting enzyme 2 (ACE-2) receptors in other organs. It was suggested that ACE-2 expression in the kidneys can be the cause of kidney injury occurring in a number of patients with SARS-CoV-2.However, ACE-2 is not the only possible cause of kidney injury - sepsis-related cytokine storm can also lead to damage of kidney parenchyma.

The present study aims to explain the mechanisms of kidney injury in patients diagnosed with COVID-19.
Associations of prolamines (I) and vegetable polar lipids (II) in a proportion that gives a stable film. The prolamine (I) is preferably zein obtained from maize, or gliadin obtained from wheat.  The polar lipids (II) contain a high proportion of ceramides and glycosyl ceramides and are preferably obtained from wheat.  The compositions may be formulated as aqueous-alcoholic gels, or as preformed films or patches, optionally with a plasticizing agent and a therapeutic or cosmetic agent.  The preferred compositions contain 20 - 40% by weight (I), 0.1 - 5% (II) the remainder being 35 - 80% aqueous ethanol.  These compositions are prepared by mixing small portions of (I) with aqueous ethanol at 42 - 48 deg C with vigorous stirring, adding (II) optionally with additives, and stirring vigorously for 20 - 40minutes at the same temperature, then leaving the mixture to cool with moderate stirring.
Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper type 1 or T helper type 2 response is modulated. In one embodiment, the agent is a stimulatory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In another embodiment, the agent is an inhibitory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In various embodiments, the immune cell is a human immune cell, a macrophage, a T cell or a non-T, non-B spleen cell. In a preferred embodiment, the invention provides methods of stimulating a specific immune response to an antigne in vivo using a stimulatory agent of the invention. In another preferred embodiment, the invention provides methods for inhibiting allergic responses in vivo using an inhibitory agent of the invention. Pharmaceutical compositions for modulating immune responses comprising the stimulatory or inhibitory agents of the invention are also provided.